Viridian Therapeutics Inc’s recent filing unveils that its Chief Operating Officer Beetham Thomas W. acquired Company’s shares for reported $0.12 million on Sep 27 ’24. In the deal valued at $23.41 per share,5,000 shares were bought. As a result of this transaction, Beetham Thomas W. now holds 6,000 shares worth roughly $0.11 million.
Then, Mahoney Stephen F. bought 21,400 shares, generating $499,262 in total proceeds. Upon buying the shares at $23.33, the President and CEO now owns 21,400 shares.
Before that, Fairmount Funds Management LLC bought 1,600,000 shares. Viridian Therapeutics Inc shares valued at $30,000,000 were divested by the Director at a price of $18.75 per share. As a result of the transaction, Fairmount Funds Management LLC now holds 3,445,813 shares, worth roughly $61.23 million.
Wells Fargo downgraded its Viridian Therapeutics Inc [VRDN] rating to an Equal weight from a an Overweight in a research note published on December 19, 2024; the price target was decreased to $27 from $37. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late November with a ‘”a Buy”‘ rating. Needham also remained covering VRDN and reiterated its “Buy” recommendation on September 11, 2024. Wolfe Research started covering the stock on June 11, 2024. It rated VRDN as “an Outperform”.
Price Performance Review of VRDN
On Monday, Viridian Therapeutics Inc [NASDAQ:VRDN] saw its stock fall -2.36% to $17.77. Over the last five days, the stock has lost -11.99%. Viridian Therapeutics Inc shares have fallen nearly -7.30% since the year began. Nevertheless, the stocks have fallen -25.40% over the past one year. While a 52-week high of $27.20 was reached on 01/07/25, a 52-week low of $11.40 was recorded on 01/13/25. SMA at 50 days reached $20.63, while 200 days put it at $17.41.
Levels Of Support And Resistance For VRDN Stock
The 24-hour chart illustrates a support level at 17.49, which if violated will result in even more drops to 17.22. On the upside, there is a resistance level at 18.12. A further resistance level may holdings at 18.48. The Relative Strength Index (RSI) on the 14-day chart is 38.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.01%. Stochastics %K at 25.48% indicates the stock is a holding.
How much short interest is there in Viridian Therapeutics Inc?
A steep rise in short interest was recorded in Viridian Therapeutics Inc stocks on 2024-12-31, growing by 3.3 million shares to a total of 12.05 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 8.75 million shares. There was a rise of 27.39%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 06, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $23 price target.
